Edward S. Kim, MD, MBA, FACP, FASCO

Neoadjuvant atezolizumab conferred a 21% major pathologic response rate among patients with resectable stage IB to stage IIIB non-small cell lung cancer.

Single-fraction stereotactic body radiation therapy appeared safe and effective for patients with up to three oligometastatic lung tumors, according to results of the phase 2 SAFRON II trial presented at the virtual ASTRO Annual Meeting.

Edward S. Kim, MD, chair of the department of solid tumor oncology and investigational therapeutics at Levine Cancer Institute at Atrium Health, spoke with Healio about how COVID-19 has affected cancer care delivery.

Edward S. Kim, MD, chair of the department of solid tumor oncology and investigational therapeutics at Levine Cancer Institute at Atrium Health, spoke with Healio about the impact COVID-19 has had on delivery of cancer care at his institution.

Two novel blood assays demonstrated efficacy in detecting various cancer types at different disease stages, according to results of two studies presented at ASCO Breakthrough in Bangkok.

NEW YORK — This year’s HemOnc Today New York meeting kicked off with a session dedicated to treatment advances and challenges in lung cancer.

CHICAGO — Edward S. Kim, MD, chair of solid tumor oncology and investigational therapeutics at the Levine Cancer Institute, and a HemOnc Today Editorial Board member, discusses results of a study presented at the ASCO Annual Meeting that demonstrated that an ultra-deep sequencing technique detected circulating tumor DNA in plasma at high rates of concordance with tumor tissue among patients with various cancers, including lung cancer.

CHICAGO — Edward S. Kim, MD, chair of the department of solid tumor oncology at Levine Cancer Institute at Carolinas Healthcare System and a HemOnc Today Editorial Board member, discusses various advances within the treatment landscape of lung cancer at the ASCO Annual Meeting.

Clinical response to neratinib varied by tumor and HER-2 mutation type, according to results from the global, multicenter phase 2 SUMMIT trial presented at the American Association for Cancer Research Annual Meeting.

CHICAGO — The ASCO Annual Meeting featured several “transformative” abstracts, according to Edward S. Kim, MD, chairman of solid tumor oncology at Levine Cancer Institute at Carolinas HealthCare System and a HemOnc Today Editorial Board member.